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1. Introduction
With the evolution in our understanding of the human leukocyte antigen (HLA) system, there
have been substantial improvements in the HLA-typing techniques and the ability to detect
anti-HLA antibodies, allowing accurate assessment of immunological risk among potential
renal transplant candidates. Specifically, flow cytometry and the solid phase assay such as the
enzyme-linked immunosorbent assay (ELISA) and Luminex technology have improved the
sensitivity of detecting low levels class I and II donor-specific anti-HLA antibodies (DSA).
Although there is now established evidence showing the presence of DSA is associated with
a greater risk of antibody-mediated rejection (AMR) and early graft loss, the clinical signifi‐
cance of low levels DSA remains unclear. As a result of prior sensitizing events, there has been
an expansion in the number of highly sensitized transplant candidates with multiple anti-HLA
antibodies. Management of these candidates for the preparation of transplantation continues
to be a subject of intense debate. In this chapter, we will discuss the identification of potential
clinically relevant DSA detected by the different assays including the ‘acceptable’ level of
clinically significant DSA and the advantage of C1q-positive DSA in further stratifying the
immunological risk of transplant candidates. The association between DSA and non-DSA with
graft and patient outcomes following kidney transplantation will be discussed in greater detail.
Furthermore, we will examine the transplant outcomes of highly sensitized patients under‐
going desensitization regimens and to determine the optimal desensitization regimens along
with their risks and benefits.
© 2013 Dheda et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Evolution of techniques to detect donor-specific anti-HLA antibodies
(Figure 1)
HLA forms part of the major histocompatibility complex (MHC) in humans and MHC antigens
are an integral component of the normal functioning of the human immune system. HLA
antigens play a crucial role in the recognition of self-antigens and are therefore crucial in the
defence of foreign antigens, including donor antigens in solid organ transplantation. HLA
antigens are comprised of both class I and II antigens, with class I antigens being expressed
on all nucleated cells, whereas class II antigens are being expressed on antigen presenting cells,
B cells and endothelial cells [1]. The evolution in our understanding of the HLA system is
closely linked to advancements in technology. Traditional serological-based (i.e. antibody-
based) low-resolution techniques have been the standard method for HLA typing, enabling
efficient and effective anti-HLA antibody detection. However, these techniques are dependent
on the availability of specific cell types, cell viability and appropriate anti-sera that are capable
of recognising HLA antigens. The emergence of molecular HLA typing techniques over the
past two decades has allowed for a more specific and robust method of high resolution HLA
typing. In 1982, Wake et al described restriction fragment length polymorphism (RFLP), which
eventually highlighted the shortcomings of serology-based methods ensuing the establish‐
ment of molecular-based HLA-typing for routine detection of anti-HLA antibodies pre-
transplantation [2]. Data generated via the genome project and the initiation of polymerase
chain reaction (PCR) techniques through the 1980s further refined DNA-based techniques for
HLA-typing, which has led to the development of a number of PCR-based techniques still in
use to the present day.
Alongside with the advances in the typing of HLA alleles, the techniques used to detect anti-
HLA antibodies has evolved from CDC assays to the more sensitive techniques including flow-
cytometry and solid-phase assays (e.g. enzyme-linked immunosorbent assay [ELISA] or
Luminex), allowing for accurate assessment of pre-transplant immunological risk (e.g.
calculated panel reactive antibodies to determine level of sensitization and application of
virtual cross-match to determine transplant suitability) [3] (Figure 4).
Since the recognition of the clinical importance of CDC assay in kidney transplantation in the
1960s, CDC cross-match has become the foundation of determining transplant suitability in
kidney transplantation [4]. CDC cross-match can detect donor-specific anti-HLA antibodies
that may have the potential to induce an anti-HLA antibody-associated hyperacute rejection
following transplantation. Donor T and B cells are isolated from peripheral blood mononuclear
cells using density gradient separation and incubated in the presence of recipients’ sera and
complements. If donor-specific anti-HLA antibodies are present, these will bind to specific
antigen(s) expressed on donor cells, and with the addition of rabbit serum as a source of
exogenous complement, will result in the initiation of the classical complement cascade
causing direct damage to the donor cell membrane and therefore making these cells permeable
to an important dye. The percentage of cell lysis is quantified and forms the basis of deter‐
mining transplant candidate’s suitability for transplantation with a lysis score of 20% generally
considered a contraindication for transplantation. Many laboratories perform CDC assays in
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the presence of anti-human globulin, which augments the sensitivity of this assay by increasing
the number of Fc receptors available to bind complements, and/or dithiothreitol (which breaks
HLA – human leukocyte antigen, CDC-XM – complement-dependent cytotoxicity cross-match, FCXM – flow cytometric
cross-match, ELISA – enzyme-linked immunosorbent assay.
Figure 1. Detection of anti-HLA antibodies – differences between cell-based and solid-phase assays.
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down the disulfide bonds in IgM antibodies believed to be of no clinical significance) to reduce
the false positivity of these assays [5, 6]. Initial studies evaluating the clinical validity of CDC
assays demonstrated that 80% of CDC cross-match–positive kidney transplants and 4% of
cross-match–negative kidney transplants were associated with early graft loss, thereby
verifying the clinical significance of anti-HLA antibodies in renal transplantation. It is note‐
worthy that 20% of patients transplanted across a positive cross-match did not lose their grafts
[3]. Given that T cells express class I antigens and B cells express both class I and II antigens,
the interpretation of T cell together with B cell cross-match will assist in establishing whether
class I and/or II anti-HLA antibodies are present. A positive B cell CDC cross-match invariably
accompanies a positive T cell CDC cross-match but this may reflect either anti-HLA antibodies
to class I antigens and/or multiple antibodies to class I and/or II antigens. However, a positive
B cell CDC cross-match may occur in the absence of a positive T cell CDC cross-match and
suggest the presence of class II antigens or low levels class I antigens. The presence of a positive
T cell CDC cross-match is an absolute contraindication for transplantation whereas a positive
B cell cross-match is a relative contraindication because of the uncertainty regarding the clinical
significance and the chance of false-positive results [7, 8]. The presence of a positive T cell cross-
match is an absolute contraindication for transplantation within the deceased donor kidney
allocation algorithm in Australia and New Zealand. \On the contrary, B cell cross-match is
not routinely performed and therefore not utilized in the decision-making process for trans‐
plantation. With the increasing recognition of the potential importance of a positive CDC B
cell cross-match, these results are now often interpreted in the context of solid phase assays.
The immunological risk of potential renal transplant candidates are established by regular
monitoring and storage of their sera to establish peak and current immune reactivity against
a panel of donor cells, termed peak and current panel reactive antibodies. When a potential
donor becomes available, donor cells are incubated in the presence of both peak and current
sera. The presence of a positive CDC cross-match with peak sera even in the presence of a
negative CDC cross-match with current sera poses a contraindication to transplantation, as
this suggests suggest immunological memory to donor antigens from prior sensitizing events.
The inability to correlate all graft losses to anti-HLA antibodies detected using CDC assays
(i.e. an inability of CDC assays to detect low levels of clinically significant anti-HLA antibodies)
has led to the development of the more sensitive cell-based flow cytometric cross-match assays.
The fundamental principle that forms the basis of the flow cytometric cross-match assay is
similar to that of the CDC assay. Since the description of this assay in the early 1980s, this
technique has been widely adopted to determine transplant suitability in many countries [9].
Similar to the CDC assay, flow cytometric cross-match assays require the addition of donor
cells to recipients’ sera, followed by the addition of a fluorescein-labelled secondary antibody
allowing for the detection and quantification of anti-HLA antibodies by flow cytometer
expressed as mean channel shifts. Unlike CDC cross-match, flow cross-match identifies both
complement-fixing and non-complement-fixing anti-HLA donor-specific antibodies. Howev‐
er, the availability of different subtypes of detection antibodies has allowed clinicians to
differentiation between complement-fixing versus non-complement-fixing anti-HLA antibod‐
ies [10]. Although an universal mean channel shifts cut-off value corresponding to positive
flow cross-match has not been determined, it is generally accepted that the use of a low cut-
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off value may disadvantage many transplant candidates as it may detect anti-HLA donor
specific antibodies of no clinical significance, especially in the presence of negative CDC cross-
match. Nevertheless, several studies have shown that the presence of a positive flow cytometric
cross-match with a negative CDC cross-match is associated with a significantly greater risk of
AMR and early graft loss with a positive predictive value for predicting AMR of 83% [10, 11].
To avoid problems associated with the availability and viability of donor cells that could affect
the accuracy of cell-based assays, solid-phase assays were introduced which have largely
circumvented these problems and improved the sensitivity of detection of anti-HLA antibodies
[12]. The identification of anti-HLA antibodies using ELISA was first described in 1993 where
purified HLA antigens were directly immobilized on the surface of microtitre plates but the
basic principle of antibody detection was similar to cell-based assays [13]. The Luminex
platform is a solid-phase assay that utilizes polystyrene microspheres (beads), each embedded
with fluorochromes of differing intensity attached to one (single-antigen beads) or several
HLA molecules (screening beads) to determine anti-HLA antibody specificity. The Luminex
assay has been used in many transplant centres to select the appropriate desensitization
regimen according to DSA strength and to establish an acceptable DSA cut-off that may allow
kidney transplantation to proceed following desensitization [14, 15]. Similar to other assays,
the addition of recipients’ sera containing anti-HLA antibodies are added to the bead mix,
these antibodies will bind to the appropriate beads expressing single or multiple specific
antigen(s). A phycoerytherin-labelled secondary anti-human IgG is then added to this mixture
and these antibodies will bind to the primary anti-HLA antibody already attached to the beads
expressing the antigens. The sample is then passed through lasers, which would independently
excite the beads and the phycoerytherin, therefore allowing the laser detector to define
antibody specificity [16, 17]. Unlike the CDC assays, Luminex assay detect both complement-
fixing and non-complement-fixing anti-HLA antibodies but does not detect IgM autoantibod‐
ies or non-HLA antibodies. The concept of virtual cross-match using solid phase assays relies
on accurate HLA typing accompanied by evaluation of anti-HLA antibodies. The presence of
a negative solid phase virtual cross-match reliably excludes the presence of donor-specific anti-
HLA antibodies and is capable of predicting a negative flow cytometric cross-match in >90%
of cases and CDC cross-match in 75% of cases. With the continued reliance on using cell-based
cross-match assays, especially CDC cross-match assays to determine transplant suitability, a
potential disadvantage of virtual cross-match is that transplants may be excluded based on
antibody results with unknown clinical relevance [18]. It is generally accepted that solid phase
virtual cross-match to identify anti-HLA donor specific antibodies complements the results of
cell-based assays to help inform decision-making process with regards to transplant suitability.
3. Association between anti-HLA donor-specific antibodies and transplant
outcomes (Table 1)
Despite technological advances in detecting pre-transplant DSA, the incidence of acute and
chronic AMR appears to increase over time. However, the true incidence of AMR remains
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Study Cohort Rejection Graft survival
Eng H et al
[24]
N=471 DD renal transplant
recipients
83 T-B+ XM vs 386 T-B- XM
IgG DSA in 33% of T-B+ XM
patients
Vascular: 19% T-B- XM vs 32% T-B+ XM
(p=0.01)
DSA+ significantly predict vascular or
glomerular rejection
Graft loss: T-B+ 44% vs T-B-
27%
Lefaucheur C
et al [25]
N=402 DD renal transplant
recipients
Peak sera: positive DSA 21%
(Luminex)
Current sera: positive
DSA 19%
PPV for AMR with peak DSA 35% vs
current DSA 32% Prevalence of AMR
categorized by MFI:
MFI <465 – prevalence 1%
MFI 466 to 3000 – prevalence 19%
MFI 3001 to 6000 – prevalence 36%
MFI >6000 – prevalence 51%
Peak DSA MFI predicted AMR better
than current DSA MFI
5 and 8-year DCGS:
Non-sensitized - 89% and 84%
Sensitized with no DSA - 92%
and 92%
DSA-positive - 71% and 61
Relative risk for graft loss if
AMR 4.1 (95% CI 2.2 to 7.7) vs
no AMR
Lefaucheur C
et al [26]
N=237 LD/DD renal transplant
recipients
All negative T and B-cell
CDC-XM
27% class I or II anti-HLA
antibody with 52% anti-HLA
antibody being DSA
Incidence of AMR: preformed DSA 35%
vs no DSA 3%
(p < 0.001)
Overall graft survival at 8 years:
DSA-positive 68%
DSA-negative 77%
Graft survival lower in patients
with DSA and AMR compared
to DSA and no AMR and in
non-DSA patients
Mujtaba M
et al [34]
N=44 desensitized LD
transplant recipients
Negative CDC T-cell XM
Sensitization = CDC B+
& T+ ± B+ flow XM
Incidence AMR 31%
Total MFI and AMR: <9500 7%
vs >9500 36%
Class II DSA but not class I DSA
greater risk of AMR
3-year graft survival was 100%
for total MFI <9500 vs 76% for
total MFI >9500.
Amico P et al
[94]
N=334 LD and DD renal
transplant recipients 332
negative T and B cell CDC-XM
67 DSA vs 267 no DSA
(Luminex)
Overall incidence of clinical/subclinical
rejection including AMR and/or acute T-
cell mediated rejection at day 200 post-
transplant: DSA-positive 71% vs DSA-
negative 35%
5-year DCGS: No DSA 89% vs
DSA without AMR 87% vs DSA
with AMR 68%
Song EY et al
[95]
N=28 LD and DD renal
transplant recipients Positive
flow XM but negative CDC-T
cell XM, 57% positive DSA
BPAR: DSA-positive 56% vs DSA-negative
0%
Class II > class I DSA higher incidence of
AMR: 100% vs 22% Class II DSA MFI of
4487 predicted AMR with sensitivity of
100% and specificity of 87%.
No difference in graft survival
HLA – human leukocyte antigen, DD – deceased donor, LD – live-donor, CDC-XM – complement dependent cytotoxicity
cross-match, DSA – donor-specific antibodies, SAB – single antigen bead, AMR – antibody mediated rejection, DCGS –
death-censored graft survival, MFI – mean fluorescent intensity, BPAR – biopsy-proven acute rejection, PPV – positive
predictive value.
Table 1. Association between pre-transplant donor-specific antibodies and graft outcomes.
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unclear with suggestions that acute AMR may account for up to 7% of all acute rejections (and
up to 50% of acute rejection episodes experienced by pre-sensitized patients with positive
cross-match); whereas the prevalence of chronic AMR manifesting as transplant glomerulop‐
athy may be as high as 20% at 5 years post-transplant [19, 20]. The growing incidence may be
attributed to a number of plausible reasons including: greater acceptance of highly-sensitized
candidates for transplantation, the use of non-calcineurin-inhibitor-based immunosuppres‐
sive regimen such as mammalian target of rapamycin inhibitors, better detection techniques
for DSA, availability of markers of antibody injury such as C4d staining and a greater under‐
standing of AMR, which may have been misinterpreted as chronic allograft nephropathy or
undefined rejection in the past [21].
In most countries, a large proportion of renal transplant candidates on the transplant wait-
list are sensitized with high PRA levels and have multiple anti-HLA antibodies, which often
result in protracted wait-list time [22]. In Australia, 23% of transplant candidates have a
peak class I PRA of >20% and these sensitized transplant candidates often have twice as long
a waiting time as unsensitized candidates [23]. Pre-transplant DSA is a major immunologi‐
cal hurdle for successful kidney transplantation. The clinical importance of pre-transplant
DSA has been clearly established over the past decade and the presence of high levels of
pre-transplant class I (HLA-A and B) ± II (HLA-DR) DSA, typically occurring as a result of
prior sensitizing events including previous blood transfusions, HLA-mismatched trans‐
plants and/or pregnancy, is associated with inferior graft outcomes, including an increased
risk of developing acute and chronic antibody-mediated rejection (AMR), transplant glomer‐
ulopathy and late graft loss (Table 1) [24-27]. However, few studies have suggested that the
association between pre-transplant DSA and graft survival was restricted to recipients who
had developed early AMR or those with high levels of DSA as determined by peak HLA-
DSA strength expressed as mean fluorescent intensity (MFI) using Luminex technology and
that pre-transplant screening for preformed DSA may not be cost-effective [28, 29]. Lefau‐
cheur C et al demonstrated in a large single centre study that renal transplant recipients with
a peak pre-transplant DSA >465 MFI determined by Luminex have a significantly higher
risk of developing AMR and that recipients with peak DSA >3000 have almost a four-fold
increase in the risk of graft loss compared to recipients with peak DSA MFI of <3000 high‐
lighting the importance of using DSA strength to more accurately assess the immunological
risk of transplant recipients [29]. There is also increasing evidence demonstrating that the
development of de novo DSA may occur in over 50% of renal transplant recipients at 2-years
post-transplant suggesting that regular monitoring of de novo DSA post-transplant may
help identify those at risk of developing poorer graft outcome [30]. Several studies have
shown that the development of de novo DSA (occurring post-transplantation), especially
DSA directed against HLA-DQ graft molecules in HLA-class II incompatible graft transplan‐
tations, are both associated with acute and subclinical AMR and graft loss in kidney trans‐
plant only and/or simultaneous pancreas-kidney transplant recipients and post-transplant
monitoring of DSA could potentially help clinicians to individualize the amount of immuno‐
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suppression to better assess immune reactivity [25, 30-33]. Although there is no current con‐
sensus on the level of clinically significant DSA identified by flow cytometric or Luminex
assays, most studies have demonstrated that increasing single, peak or total DSA levels
were associated with an incremental risk of rejection and/or graft loss [29, 34]. Recent stud‐
ies have suggested that the detection of C1q-fixing DSA (i.e. the potential to identify DSA
that can activate complements by binding C1q) may be more accurate in predicting acute
rejection, biopsy C4d-deposition, transplant glomerulopathy and late graft failure following
kidney transplantation and the authors suggested that the absence of C1q-positive de novo
DSA has a high negative predictive value for transplant glomerulopathy (100%) and graft
failure (88%) [35]. However, a recent retrospective study showed that the identification of
strong complement-activating DSA (of IgG subclasses 1 and 3) pre-transplant was unlikely
to improve AMR risk stratification compared to patients with a combination of both strong
and weak/no complement-activating DSA (of IgG subclasses 2 and 4) [36]. The clinical im‐
portance of C1q-specific DSA in predicting graft outcome remains controversial and not
routinely performed in many transplanting centres [35, 37]. With the greater understanding
of HLA antigens and anti-HLA antibodies, innovative techniques have been established to
allow transplantation across positive CDC and/or flow cross-match barriers by removing
circulating DSA and/or B or plasma cells and the success and outcomes of these initiatives
will be discussed later in this chapter.
4. Clinical relevance of non-anti-HLA donor-specific antibodies (Table 2)
Although it is well established that AMR is attributed to the presence of class I and/or II DSA,
non-donor HLA-antibodies and other non-HLA antibodies have been implicated in the
development of acute and chronic AMR following kidney transplantation. Opelz G et al and
others have demonstrated that increasing panel reactive antibodies (PRA) in HLA-identical
sibling transplants was associated with a greater risk of rejection (defined as functional graft
survival) and poorer graft survival (PRA 0% 10-year graft survival 72%, PRA 1-50% 63%, PRA
>50% 55%; o<0.01) suggesting that immune response against non-HLA targets may be
important in kidney transplantation, especially in the prediction of chronic graft loss [38].
Alloantigenic and tissue-specific autoantigenic targets of non-HLA-DSA and non-HLA
antibodies may include various minor histocompatibility antigens, major histocompatibility
complex (MHC) class I chain-related gene A (MICA) antigens, endothelial cell, vimentin,
collagen V, glutathione-S-transferase T1, agrin, and angiotensin II receptor type I. Table 2
provides an up-to-date summary of the significance of these non-HLA-DSA and non-HLA
antibodies in kidney transplantation and discuss the interplay between alloimmunity and
autoreactivity in renal allograft rejection [39, 40].
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Antibodies HLA-
antigen
(Yes/No)
Target antigen Location Transplant outcomes
Anti-angiotensin type
1–receptor antibody
[96,97]
No Angiotensin type I
receptor (cell-based
ELISA)
Endothelial cells Increased risk of ACR, vascular
rejection and AMR ± malignant
hypertension
MICA antibody [98] Yes Major histocompati-
bility-complex class I
related chain A antigens
(Luminex)
Endothelial cells
(also fibroblasts,
epithelial cells)
Increased risk of rejection and
graft failure, remains debatable
Anti-endothelial cell
antibody [39,99]
No Endothelial cell
precursors (flow
cytometry)
Endothelial cells Increased risk of acute and
chronic rejections
Vimentin antibody [100] No Intermediate filament
protein (flow cytometry)
Endothelial cells Increased risk of rejection
Agrin antibody [101] No Highly purified GBM
heparan sulphate
proteoglycans (ELISA)
GBM Increased risk of transplant
glomerulopathy
Glutathione-S-transferase
T1 antibody [40]
No Glutathione-S-
transferase T1 enzyme
(ELISA)
Endothelial cells Increased risk of C4d-negative
acute and chronic AMR
Anti-GBM antibody [102] No Alpha-3 chain (the
Goodpasture antigen)
and alpha-5 chain of
type IV collagen (ELISA)
GBM Increased risk of vascular
rejection (Alport patients)
Antibodies to MIG (also
called CXCL9), ITAC (also
called CXCL11), IFN-γ, and
glial-derived neurotrophic
factor [103]
No Chemokine or cytokine
(ELISA)
Circulating
proteins
Association with chronic renal
allograft injury
Protein kinase Czeta
antibody [104]
No Protein kinase
(microarray)
Kidney and
lymphocytes
Increased risk of graft loss
Anti-HLA-Ia
antibody [105]
Yes HLA-Ia alleles Endothelial cells Correlate with poorer graft
survival, possibly mediated via
anti-HLA-E IgG antibody
Abbreviations: MICA – major histocompatibility complex class I chain-related gene A, ACR – acute cellular rejection, AMR
– antibody mediated rejection, GBM – glomerular basement membrane, ELISA – enzyme-linked immunosorbent assay,
HLA – human leukocyte antigen
Table 2. Association between non-HLA-DSA and non-HLA antibodies and renal transplant outcomes.
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5. Complexities in the diagnosis of antibody mediated rejection (Table 3)
The diagnosis of AMR has improved dramatically with the advent of C4d staining and the
ability to detect DSA [41]. The diagnosis of acute AMR according to BANFF criteria requires
a triad of [1] histological evidence of graft damage including acute-tubular necrosis-like
minimal inflammation, capillaritis and/or glomerulitis and/or thromboses and arteritis, [2]
immunological evidence of complement activation inferred by C4d positivity in the peritub‐
ular capillaries (PTC), and [3] presence of DSA; whereas the diagnostic criteria for chronic
AMR requires [1] morphological evidence of chronic damage of the allograft including
duplication of glomerular basement membrane, lamination of peritubular capillaries, arterial
intimal fibrosis or interstitial fibrosis/tubular atrophy, [2] diffuse C4d deposition in PTC, and
[3] presence of DSA [42]. C4d, a complement split product, is formed by the binding and
activation of the classical complement pathway by DSA, which then binds covalently to
specific target molecules on the endothelium of PTC and is therefore considered a footprint of
AMR [43]. The sensitivity and specificity of diffuse PTC C4d staining for the presence of DSA
is >95% [44].
Acute antibody-mediated rejection
Peritubular capillary C4d deposition
Circulating anti-HLA donor specific antibody
Morphological evidence of acute tissue injury (e.g.
capillaritis, glomerulitis)
Chronic antibody-mediated rejection
Peritubular capillary C4d deposition
Circulating anti-HLA donor specific antibody
Morphological evidence of chronic tissue injury (e.g.
transplant glomerulopathy, interstitial fibrosis, tubular
atrophy)
Controversies of C4d staining
Peritubular capillary C4d deposition
Glomerular C4d deposition
Arteriolar C4d deposition
AMR
Erythrocyte C4d deposition better PPV in peritubular
capillary
Useful to detect AMR, diffuse > focal, PTC C4d negative in
60% AMR
Correlates with AMR and graft survival
No association with graft survival or Similar sensitivity and
specificity but detecting AMR compared with C4d
deposition
Abbreviation: AMR – antibody mediated rejection, HLA – human leukocyte antigen
Table 3. Histological criteria for acute and chronic antibody mediated rejection and corresponding table of
controversies of relying on peritubular capillary C4d deposition as a marker for antibody mediated rejection.
However, there are concerns regarding whether the presence of C4d within peritubular
capillaries is essential for the diagnosis of AMR with reports of C4d-negative AMR being
identified. There have been a few studies that have demonstrated an association between
glomerular or erythrocyte C4d deposition and the presence of acute and chronic AMR but the
clinical significance of these deposits remain debatable.
Problems with C4d staining:
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i. Accomodation
The presence of C4d deposition in PTC does not always denote the presence of AMR or tissue
injury. In ABO-incompatible renal transplant, the presence of PTC C4d staining often occurs
in the absence of tissue injury or AMR, a process known as accommodation and may be
observed in >70% of ABO-incompatible transplants; whereas the presence of PTC C4d staining
in HLA-incompatible grafts correlates strongly with the presence of AMR [45].
ii. C4d negative AMR
AMR in the absence of PTC C4d staining has been reported more frequently. In an analysis of
173 indication kidney biopsies, Sis et al demonstrated that a combination of high expression
of endothelial-associated transcripts (ENDAT) detected using microarray on tissue biopsy,
suggesting endothelial damage from alloantibody, plus the presence of DSA was strongly
associated with morphological evidence of AMR but only 38% of these biopsies had evidence
of PTC C4d positivity [46]. Other studies have corroborated this initial finding suggesting that
over reliance of C4d positivity to diagnose acute or chronic AMR could miss up to 60% of
patients with morphological evidence of AMR and C4d staining should always be interpreted
in the context of tissue morphology [47, 48]
iii. Focal versus diffuse C4d staining
It is generally accepted that the detection of C4d in renal allograft biopsies using immuno‐
fluorescence staining is more sensitive than immunohistochemical staining [42, 49]. The level
of C4d staining appears to have prognostic significance and it is widely accepted that diffuse
C4d staining involving >50% of PTC by either technique is considered positive and correlates
much more strongly with adverse graft outcome compared to focal C4d staining involving
<50% of PTC, but this remains controversial [50]. However, there are other studies suggesting
that focal C4d staining is also associated with histological evidence of AMR including
glomerulitis and/or peritubular dilatation [51].
iv. Non-PTC C4d staining
Glomerular, arteriolar and/or erythrocyte C4d positivity often occurs in the absence of PTC
C4d staining but the clinical significance of these patterns remains unclear. In a retrospective
study of 539 indication renal allograft biopsies, Kikic et al demonstrated a poor correlation
between arteriolar C4d staining and graft survival, whereas linear glomerular C4d staining
was strongly associated with graft failure [52]. There has been considerable interest in the
detection of erythrocyte C4d deposition (eC4d) by indirect immunofluorescence as a potential
surrogate marker of disease activity in patients with systemic lupus erythematosus and may
be useful for the monitoring of disease activity and/or response to treatment in these patients
[53, 54]. In kidney transplantation, Haidar et al showed a greater amount of eC4d in PTC C4d
positive samples compared to PTC C4d negative samples. The authors reported that the
positive (PPV) and negative predictive value (NPV) of PTC C4d and eC4d for peritubular
capillaritis were 28% and 46% for PPV and 93% and 94% for NPV respectively suggesting that
monitoring of eC4d may be an useful non-invasive marker of AMR [55].
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6. Management of highly sensitized renal transplant candidates with anti-
HLA antibodies
The complexity of transplantation has evolved over the years such that many transplanting cen‐
tres are performing ABO-incompatible transplants and desensitizing highly allo-sensitized
transplant candidates to improve their transplant potential. There is an increasing number of
transplant candidates who are allo-sensitised to HLA as a result of previous exposure to HLA an‐
tigens, typically following blood transfusion, prior transplantation and pregnancy. It is well
known that the presence of high levels of pre-transplant DSA is associated with poorer graft out‐
comes, including the development of acute and chronic AMR resulting in late graft loss [26, 56].
Finding a compatible donor for potential transplant candidates with multiple anti-HLA antibod‐
ies is often difficult and these patients may remain on the deceased donor transplant wait-list for a
much longer period compared to unsensitized transplant candidates. Paired kidney exchange
program is a potential and proven option for highly sensitized patients who have a positive cross-
match with their potential live donors to receive a compatible cross-match negative donors [57].
With the greater understanding of HLA antigens and anti-HLA antibodies, innovative techni‐
ques have been established to allow transplantation across a ‘positive CDC and/or flow cytomet‐
ric  cross-match’  barrier  resulting  from  anti-HLA  antibodies  directed  against  the  donor.
Nevertheless, graft outcomes of highly sensitized transplant recipients are poorer compared to
compatible transplant recipients, particularly a much greater risk of acute AMR (Table 4).
Number of
patients AMR incidence (%)
1-year graft survival
(%)
2-year graft survival
(%)
Lefaucheur et al ^ [26] 43 35 89 89
Thielke et alθ [70] 51 32 93 81
Magee et al [71] 28 39 92 89
Gloor et al [106] 119 41 89 89
Haririan et al [106] 41 12 90 85
Vo et al [72] 16 30 94 Not reported
Vo et al# [62] 76 29 87 84
ANZDATA 2010* [107]
Primary DD grafts
Primary LD grafts
550
296
<5%
<5%
95
96
93
96
*ANZDATA 2010 – graft failure secondary to AR 2%; #Stratified by donor type – death-censored graft survival at 1 and
2 years for LD 90% and 90%; for DD 82% and 80%. [Note: Of the total 374 recipients, only 51 [13.6%) were DD
transplants].
Acute AMR is a strong predictor of inferior graft survival: 1] ^AMR vs no AMR – 1y GS 60% vs 89% (Lefaucheur et al); 2]
θAMR vs no AMR – development of transplant glomerulopathy 44% and 12% (Gloor et al).
Abbreviations: ANZDATA – Australia and New Zealand Dialysis and Transplant registry, AMR – antibody mediated
rejection, DD – deceased donor, LD – live-donor.
Table 4. Incidence of antibody mediated rejection and graft survival following positive crossmatch kidney
transplantation.
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Number Technique Outcomes Complications
Vo A et al [72] • 10/11 LD and 6/9 DD
with CDC-XM or FCMX+
(Note: 13/16 had
persistently positive
XM at time of transplant)
• IVIg 2g/kg day 0 and
30 + rituximab 1g day
7 and 22
(5/16 CDC-XM+)
• Wait-time pre-
transplant 144±89m,
additional 5±6m (range
2-18) post-
desensitisation
• 12mGS 94%
• 12mPS 100%
• 50% AR (30%AMR)
• 44% asymptomatic
UTI
Vo A et al [62] • 76 (31 LD & 45 DD)
with T cells FCMX+
F/up 18m
• IVIg 2g/kg day 1 and
30 + rituximab 1g
day 15
• Wait-time for DD pre-
transplant 95±46m,
additional 4.2±4.5 post-
desensitisation
• AMR 29% (11DD/
11LD)
• 2yGS 84%, PS 95% (LD
90%/100%, DD 80%/
91%)
• 2yCr - 143µmol/L
• 11% infections, 8%
CMV/BKV
• 5% mortality (2.5%
infections)
Rogers N et al
[108]
• 10/13 LD with
CDCXM+ and DSA+
successful(DSA up to
18,000 MFI)
• Rituximab 375mg/m2
day -14 + 5PP with
0.1g/kg post-4PP +
2g/kg IVIg post-final PP
• Induction basiliximab
• 80% Cr <160
• 30% AR (cellular) <3m
(Pre-Tx DSA <5000)
• 10% PNF
• 10% mortality
(sepsis)
• 70% transfusions ≥5
units
• 30% sepsis
• 21% CMV
Haririan A et al
[69]
• 41 LD with FCMX+ with
27 B/T cell+ (vs historical
controls)
• Alternate day PP
(mean 4) + post-PP
0.1g/kg
IVIg + induction T cell
depletion
• 1y GS – 90% vs 98%
(historical controls)
• 5y GS – 69% vs 81%
• Graft half-life 6.8y
• 12% AMR
• Infection rates
similar
Gloor J
et al [106]
• 119 LD +CM
(52 CDC-XM+) vs 70
controls
• Daily PP with post-PP
0.1g/kg IVIg ±
splenectomy or
rituximab (d-7) + rATG
induction
• 50% AMR and 54$ TG
in CDC-XM+ (vs 1% and
0% controls)
• DCGF 46% vs 0% at 2y
• Not reported
Thielke J et al
[109]
• 49/57 LD FCMX+
successfully desensitised
to XM-
• 3-5 PP with post-PP
0.1g/kg IVIg ± rituximab
(1-2 doses 375mg/m2)
• 1y DCGS 93%
• 1y PS 95%
• AR 43% 1y (24% AMR)
• Infection risk with
rituximab
• 7% CMV
Magee C et al
[110]
• 29 LD CDC-XM T
or B-cell +
• 3x/week PP with 10g
IVIg post-PP ± rituximab
pre-transplant
(375mg/m2)
• 42% ACR and 39%
AMR (no difference with
rituximab)
• Not significant
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Number Technique Outcomes Complications
Jordan S
et al [61]
• 98 PRA ≥50%
randomised 1:1 to
IVIg or placebo
(LD and DD)
• IVIg 2g/kg monthly for
4 months or placebo
• Improved DD
transplant rate in IVIg
group compared to
placebo (31% vs 12%,
p=0.01)
• Estimated projected
mean time to
transplantation is 4.8y
for IVIG vs 10.3y for
placebo
• GS and PS similar
• More headaches in
IVIg group
Jordan S et al
[111]
• N=42 (62% LD) • LD 1x 2g/kg IVIg
• DD monthly 2g/kg
IVIg x 4 + pre-Tx 2g/kg
IVIg
• 31% AR (<1m), 38%
ATG and 23% graft loss
from AR
• 2y GS 89%, PS 98%
• Not reported
Abbreviations: LD = live-donor, DD – deceased donor, CDC – complement dependent cytotoxicity, FCMX – flow cytometric
cross-match, DSA – donor specific antibody, PP – plasmapheresis, AR – acute rejection, rATG – rabbit antithymocyte
globulin, GS – graft survival, DCGF – death-censored graft failure, PS – patient survival, AR – acute rejection, AMR –
antibody mediated rejection, ACR – acute cellular rejection, TG – transplant glomerulopathy, IVIg – intravenous
immunoglobulin, PNF – primary non-function, CMV – cytomegalovirus
Table 5. Relevant studies of desensitization in live and deceased-donor transplantation.
Studies reporting the utilization of desensitisation techniques to allow transplantation in
highly sensitized transplant candidates have focussed predominantly on live-donor trans‐
plantation, which allows early planning and implementation of treatment at a suitable time
(Table 5). A recent paper by Montgomery R et al had demonstrated that desensitization of highly
sensitized patients for live-donor transplantation was associated with a significant survival
benefit compared with waiting for a compatible deceased donor organ. By 8 years, this survival
advantage more than doubled suggesting that desensitization protocols to overcome incom‐
patibility barriers in live-donor renal transplantation may be justified [58]. However, the
benefit of desensitization of highly sensitized patients on the deceased donor transplant wait-
list remains debatable due to the uncertainty of kidney availability [59, 60]. The only random‐
ized study evaluating the benefit of IVIg to improve transplant potential in highly sensitized
transplant candidates on the deceased donor transplant wait-list was a double-blind, placebo-
controlled, multicentre study whereby 101 patients with PRA >50% who have been waiting
for >5 years on the transplant wait-list were randomized to receive IVIg (2g/kg monthly for 4
months) or placebo. The administration of high-dose IVIg was associated with a reduction in
PRA levels with 35% of IVIg-treated patients being transplanted compared with 17% of
patients receiving placebo suggesting that this regimen was associated with improved
transplant potential for highly sensitized patients [61]. This same group modified this initial
regimen by adding rituximab and subsequently reported that desensitization of highly
sensitized patients with PRA >30% using high dose IVIg (2 doses of of 2 g/kg days 1 and 30)
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and a 1g dose of rituximab (day 15) reduced the deceased donor transplant wait-list time from
95±46 months to 4.2±4.5 months achieving acceptable rejection rates and graft survival at 24
months [62]. In contrast, a recent prospective cohort study evaluating pre-transplant desensi‐
tization with two doses of IVIg (2 g/kg up to a maximum of 120g per dose) plus a single dose
of rituximab (375 mg/m2) in highly sensitized kidney transplant candidates with a calculated
panel reactive antibody (cPRA) of >90% and had spent >5 years on the deceased donor wait-
list did not improve their transplant potential or reduced class I and II cPRA levels. This finding
has been corroborated by other studies that have demonstrated that treatment with high dose
IVIg in highly sensitized patients (flow cytometric calculated PRA of 100%) on the deceased
donor transplant wait-list did not significantly alter their cPRA levels or improved their
transplant potential highlighting that the potential benefit of desensitization of highly
sensitized transplant candidates on the deceased donor wait-list remain uncertain [63-65].
The optimal desensitization regimen for highly sensitized renal transplant candidates in the
context of living related and unrelated donation remains unclear. Most of the current desen‐
sitization protocols are modifications of plasmapheresis and intravenous immunoglobulin
(IVIg) ± rituximab and have been used successfully to desensitize highly allo-sensitized
transplant candidates, therefore allowing transplantation to occur [61, 66-73] (Table 2).
However, desensitization of positive CDC or flow cytometric cross-match patients using
immunoadsorption with rituximab followed by ongoing immunoadsorption post-transplant
appears promising achieving rapid elimination of DSA and excellent short-term graft out‐
comes [74]. Immunoadsorption appears to be more effective than plasmapheresis in removing
circulating DSA and studies have shown that a single pre-transplant immunoadsorption could
render a positive cross-match to become negative [75, 76]. Encouraging results have been
obtained with the use of bortezomib and/or eculizumab in desensitization protocols to achieve
successful transplantation across a positive CDC and/or flow cytometric cross-match barrier
but the use of these agents are usually considered adjunctive treatments to standard protocol
[77]. Although splenectomy has historically been used in the desensitization protocols for
ABO-incompatible transplants and treatment of refractory AMR by removing an essential
source of B lymphocytes, this has largely been superseded by B cell depleting agents [78]. These
techniques aim to lower the DSA to an ‘acceptable’ level pre-transplant to allow transplanta‐
tion to proceed and preventing immediate acute renal allograft injury. Most published studies
of desensitization protocols are non-randomized and observational with varying techniques
and threshold of detecting pre-transplant DSA, thereby making comparisons between studies
difficult. Plasmapheresis with low dose IVIg (0.1g/kg following each plasmapheresis) for 2-3
weeks pre-transplant followed by interleukin-2 receptor antibody or CD3-T cell depletive
agent induction is the most common desensitization protocol utilized in many transplanting
centres although the duration of treatment pre- and post-transplant would depend on
achieving a negative cross-match pre-transplant and on the DSA titres. Studies utilizing this
protocol have reported high risk of AMR (between 12-100%) with a reduction in longer-term
graft survival (66% at 4 years) despite acceptable short-term graft survival [69, 79, 80].
Although high-dose IVIg (2g/kg) was initially considered for deceased donor kidney trans‐
plant candidates, it has been implemented with and without rituximab in positive CDC
and/or flow cytometric cross-match live-donor transplant candidates with similar risk of
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rejection and graft survival to studies using plasmapheresis and low-dose IVIg [62, 80-82]. A
retrospective study by Stegall et al showed that CDC T cell cross-match positive renal transplant
recipients receiving high dose IVIg alone had a higher rate of AMR [80%) compared to
recipients receiving plasmapheresis, low-dose IVIg with rituximab (37%) or plasmapheresis,
low-dose IVIg, rituximab and pre-transplant anti-thymocyte globulin (29%) suggesting that
high dose IVIg may be inferior to the combination of plasmapheresis and IVIg but it is difficult
to draw any firm conclusion from an uncontrolled study [73]. Furthermore, there are sugges‐
tions that pre-transplant treatment to lower DSA MFI to <6000 using Luminex is recommended
for successful transplantation and is associated with lower risk of AMR but again, this remains
debatable [14].
Following successful transplantation, ongoing monitoring of DSA and early recognition of
AMR is crucial to avoid early graft loss. On re-exposure to donor antigens against which the
recipient is sensitized, memory B lymphocytes in their spleen, bone marrow and lymph nodes
undergo an anamnestic reaction leading to the development of antibody-producing cells,
which can produce high levels of DSA within days or weeks and therefore, positive cross-
match kidney transplantation requires both pre- and post-transplant interventions to contin‐
ually suppress DSA levels. Although continuing plasmapheresis and/or IVIg post-transplant
following successful desensitization of highly sensitized recipients with positive cross-match
against the donor is generally accepted, there has been no study addressing the type, amount,
duration and cost-effectiveness of such approach [70]. Nevertheless, studies have demonstrat‐
ed a strong association between the development of de novo DSA (especially DQ-DSA or when
there is a rise of DSA >500 MFI) and AMR and graft loss suggesting that that long-term
monitoring of DSA in highly sensitized patients may be appropriate, especially those receiving
class II-incompatible grafts [83-85]. A recent single centre study suggested that post-transplant
DSA surveillance followed by pre-emptive initiation of IVIg and plasmapheresis with rising
DSA titres have successfully improved long-term graft survival [86].
Intravenous gammaglobulins (IVIG) are effective in the successful management of a number
of autoimmune and inflammatory disorders attributed to their immunomodulatory and
immunoregulatory properties. IVIG has been suggested in the management of highly sensi‐
tized renal transplant patients because it eliminates eliminate circulating anti-HLA antibodies,
suppresses the production of these antibodies by inducing B cell apoptosis (and also T cells
and monocytes in vitro) and is a modifier of complement activation and injury [87, 88]. There
is now considerable debate among the transplant community regarding the balance between
the benefits and harms associated with IVIG desensitising patients with high immunological
risks. t[89, 90]. One small but significant side effect associated with the use of high dose IVIg
is the risk of thrombosis, which may be mitigated by slowing infusion rate (maximum infusion
rate of 100mg/kg/hour), aspirin, enoxaparin and intravenous hydration pre- and post-infusion
[91]. The important side effects of IVIg along with other agents commonly used in the
desensitization protocol are summarized in Table 6. However, it is important to note that many
of the side effects associated with desensitization treatment have been reported in non-
transplant population but should be recognized and advised to patients receiving these
treatments.
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Treatment Actions Complications Cost Comments
Intravenous
immuno-
globulin [112]
Neutralize circulating anti-
HLA antibodies
Enhance clearance of anti-
HLA antibodies
Inhibit complement
activation
Induce B cell apoptosis
Inhibitory effects on other
immune cells such as
macrophages and natural
killer cells by binding to their
Fcγ receptors
Thrombotic events
Acute renal failure
Haemolytic anaemia
Aseptic meningitis
Anaphylactoid reactions
US$8700
for 120g
Infusion related adverse
events related to osmolality,
minimized by slowing infusion
rate
Reduce thrombotic events by
using aspirin, heparin/
enoxaparin, intravenous fluids
Newer preparation, iso-
osmolar products have higher
titres of antiA±B, resulting in
higher rates of haemolysis
Plasmapheresis
[113]
Removal of circulating anti-
HLA antibodies
Hypotension
Bleeding diathesis
Potential blood-borne
pathogen transmission if
replacement with fresh
frozen plasma is required
(rare)
US$2000
per session
Non-selective removal of
antibodies
Immuno-
adsorption
[74, 114]
Removal of circulating anti-
HLA antibodies
Similar complications as
plasmapheresis
US1600
per session
Higher plasma volume
exchange resulting in higher
antibody removal rate may be
achieved over plasmapheresis.
More selective IgG removal
compared to plasmapheresis
Rituximab
[115]
Chimeric murine/human
monoclonal antibody that
binds to CD20 on pre-B and
mature B lymphocytes
Infection (fungal and
other opportunistic)
Progressive multifocal
leukoencephalopathy
US$3900
for 700mg
Similar effectiveness using
smaller dose
Bortezomib
[116, 117]
Proteasomal inhibitor
causing apoptosis
of plasma cells
Fatigue, weakness
Gastrointestinal
disturbances (common, mild)
Anaemia, thrombocytopenia
(mild, transient)
Peripheral neuropathy (mild,
transient)
US$1322
for 3.5mg
Role in desensitization unclear
Eculizumab
[118, 119]
Humanized monoclonal
antibody against C5
preventing the formation of
membrane attack complex
(C5b-9)
Meningococcal infections
(rare, severe)
Other infections especially
with encapsulated bacteria
Anaemia (rarely serious),
leukopenia
Hypertension, headache,
gastrointestinal upset
(common, mild)
US$5990
per 300mg
Role in desensitization unclear
Requires meningococcal
vaccination at least 2 weeks
prior to transplant
Abbreviation: HLA – human leukocyte antigens.
Table 6. Complications and cost of desensitization treatment.
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In the absence of large randomized controlled trials, the optimal desensitization protocol is
unclear. Observational data have reported desensitization protocols comprising of high or
low-dose IVIg and plasmapheresis with or without rituximab and othetr newer agents such
as bortezomib and eculizumab may be beneficial in selected patients, the rate of AMR remains
extremely high (up to 50% in pre-sensitized positive cross-match patients undergoing
desensitization) and may not be justified in circumstances such as in patients with very strong
pre-transplant DSA levels [19]. The lack of treatment effectiveness among highly sensitised
individuals is not unexpected, because most recommended treatment options such as plas‐
mapheresis, IVIg and rituximab have minimal effects on plasma cells, the critical element of
anti-HLA antibodies production, and AMR. Clinicians should discuss with their patients about
the complexities and the potential side effects associated with any desensitisation protocols,
taking into considerations the underlying immunological risks of the potential transplant
candidates, the potential benefits against the short and longer-term harms such as infection
and cancer risks. Specifically transplant candidates with prior sensitizing events and have DSA
(even at low levels) against potential donor (e.g. husband to wife transplant) are at significant
risk of AMR after transplantation despite r adequate desensitization. If desensitization is
undertaken, this should be initiated 2-3 weeks post-transplant to ensure adequate removal of
anti-HLA DSA pre-transplant with at least a negative CDC cross-match (or reduction in flow
cytometric cross-match results) and persistent reduction in DSA MFI below 2000-5000.
Transplantation should be abandoned if there is rebound of high titres DSA and/or the
crossmatches remained unchanged/positive following desensitisation protocols. Although the
benefit or cost-effectiveness of post-transplant DSA monitoring ± protocol biopsies in improv‐
ing post-transplant graft outcomes remains unclear, it is well established that de novo DSA and
rising pre-transplant DSA are associated with a greater risk of rejection and poorer graft
survival [32, 92, 93]. However, there is no data suggesting that early interventions in renal
transplant recipients who develop de novo DSA or rising DSA would result in an improvement
in graft outcomes. Nevertheless, prospective monitoring of pre-existing DSA or for de novo
DSA ± protocol biopsies should be considered and appropriate treatment instituted in those
who develop histological evidence of rejection. Several proposed desensitization and post-
transplant follow-up algorithms for positive cross-match highly sensitized recipients are
available but the cost-effectiveness and outcomes of these programs remains unknown [80].
7. Conclusion
Despite the availability of more potent immunosuppression, the incidence of AMR continues
to be an important cause of graft loss. Nevertheless, with the evolution of more sensitive
molecular-based HLA-typing and the ability to detect DSA, clinicians have the necessary facts
to critically appraise the immunological risk of each transplant candidate. However, there
continues to be debate on several major issues including the role of non-DSA in transplantation,
the appropriate DSA threshold, complexity in the diagnosis of acute and chronic AMR and
the optimal desensitization protocol for highly sensitized patients. As there continues to be an
increase in the number of highly sensitized renal transplant candidates on the transplant wait-
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list as a result of prior sensitizing events, future studies addressing all these unanswered issues
are critical.
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